Veozah works by blocking the NK3 receptor in your brain's thermostat to reduce hot flashes without hormones. Here's how it works in plain English.
Veozah (Fezolinetant) works by blocking a specific receptor in your brain that controls body temperature, which reduces hot flashes without using hormones.
If you've been prescribed Veozah — or you're thinking about asking your doctor about it — you probably want to understand what it actually does inside your body. The science behind Veozah is genuinely fascinating, and the good news is that it can be explained without a medical degree. Let's break it down.
To understand how Veozah works, you first need to understand why hot flashes happen in the first place.
Deep inside your brain, there's a region called the hypothalamus. Think of it as your body's thermostat. It constantly monitors your core body temperature and makes adjustments — widening blood vessels to release heat when you're too warm, triggering shivering when you're too cold. In normal circumstances, this thermostat has a comfortable range (called the "thermoneutral zone") where your body doesn't need to do anything — you just feel fine.
During menopause, estrogen levels drop. This drop disrupts the balance between estrogen and a brain chemical called neurokinin B (NKB). When estrogen is low and NKB levels are relatively high, the thermoneutral zone narrows dramatically. Instead of your body tolerating a normal range of temperature fluctuations, even a tiny change can trigger your brain to think you're overheating.
The result? Your body launches a full cooling response — blood vessels dilate, blood rushes to the skin, you sweat, your heart rate increases. That's a hot flash. And it can happen dozens of times a day.
Here's where Veozah comes in. Neurokinin B does its work by binding to a receptor called the NK3 receptor. Think of NKB as a key and the NK3 receptor as a lock. When the key turns the lock, it sends a signal that narrows your thermoneutral zone and makes hot flashes more likely.
Veozah (Fezolinetant) is a selective NK3 receptor antagonist. In plain English: it blocks the lock so the key can't turn it.
By blocking the NK3 receptor, Veozah prevents neurokinin B from sending those overheating signals to your brain's thermostat. Your thermoneutral zone widens back toward normal, and your body stops overreacting to minor temperature changes. Fewer false alarms means fewer hot flashes.
An analogy that might help: imagine your smoke detector (the hypothalamus) has become so sensitive that it goes off every time you make toast (normal body temperature fluctuations). Veozah doesn't remove the smoke detector — it just recalibrates the sensitivity so it only goes off when there's an actual fire.
The key thing about Veozah's mechanism is that it's targeted. It doesn't flood your body with hormones. It doesn't broadly alter brain chemistry like an antidepressant. It blocks one specific receptor that is directly involved in the hot flash pathway. That's why it's considered a precision approach to treating vasomotor symptoms.
In clinical trials, many women started noticing a reduction in hot flash frequency within the first week of taking Veozah. However, the full effect typically develops over four to twelve weeks of consistent daily use.
Here's what the timeline generally looks like:
It's important not to give up too early. If you don't notice dramatic improvement in the first few days, keep taking Veozah as prescribed. The medication needs time to fully block the NK3 receptors and allow your thermoneutral zone to stabilize.
Veozah is designed to be taken once daily. A single 45 mg dose provides 24 hours of NK3 receptor blockade. This means you maintain consistent protection against hot flashes throughout the day and night, which is particularly important for women who also suffer from night sweats.
If you stop taking Veozah, the NK3 receptors become unblocked, and hot flashes can return. Veozah does not cure the underlying cause of hot flashes (declining estrogen levels) — it manages the symptom by blocking the downstream pathway. As long as you're in the phase of menopause where vasomotor symptoms are active, you'll likely need to continue taking it.
Your doctor will periodically reassess whether you still need Veozah, since hot flashes naturally decrease over time for most women — though this can take years.
Veozah belongs to a new drug class, but it's worth understanding how it compares to other options.
HRT works by replacing the estrogen your body is no longer producing. It's the most effective treatment for hot flashes, but it comes with risks — including increased risk of blood clots, stroke, and certain cancers — that make it inappropriate for some women. Veozah offers a nonhormonal alternative that targets the hot flash mechanism directly, without adding estrogen to your system.
Lynkuet is the newest competitor, approved in October 2025. While Veozah blocks only the NK3 receptor, Lynkuet is a dual NK1/NK3 receptor antagonist. The NK1 receptor is involved in mood and sleep regulation, so Lynkuet may offer additional benefits for insomnia — a common companion to hot flashes. Both medications are nonhormonal and require similar monitoring.
Brisdelle is a low-dose SSRI (7.5 mg Paroxetine) approved for menopause hot flashes. It works by affecting serotonin levels, which has a broader effect on brain chemistry. Brisdelle doesn't require liver monitoring but can cause drowsiness, weight changes, and other SSRI-related side effects. Veozah's mechanism is more targeted — it only affects the NK3 pathway.
Medications like Effexor XR (Venlafaxine), Neurontin (Gabapentin), and Catapres (Clonidine) are sometimes used off-label for hot flashes. These medications were designed for other conditions and affect multiple systems in the body. Veozah's advantage is its specificity — it was designed from the ground up to address the NK3 pathway responsible for hot flashes.
Veozah represents a genuinely new approach to treating hot flashes. Instead of replacing hormones or broadly altering brain chemistry, it targets the specific receptor that causes your brain's thermostat to malfunction during menopause. It's a targeted, nonhormonal, once-daily treatment that starts working within the first week for many women.
The trade-off is the need for liver monitoring (because of the boxed warning for liver injury) and the cost ($550–$765 per month without savings programs). But for many women, the science behind Veozah translates to meaningful, measurable relief from one of menopause's most disruptive symptoms.
Ready to try Veozah? Learn how to find a doctor who prescribes it, then use Medfinder to find a pharmacy near you that has it in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
